All topicsTOPIC / FRONTIER COVERAGE

AI drug discovery

AI drug discovery is the use of machine learning and other computational methods to identify disease targets, design and screen candidate molecules, and predict their properties, aiming to make developing new medicines faster and more efficient.

TYPE: Topic
SIGNALS: 10
FIRST SEEN: Aug 21, 2026
LAST SEEN: Oct 27, 2026

Recent signals

Anthropic details early drug development work with six partners and says it has acquired Mithril, a one-person company working on muscular dystrophy (Anthropic) Oct 27, 2026
Pathos AI, which uses AI to develop oncology drugs, raised a $237M Series E at a $3B post-money valuation, up from $1.6B after its $365M Series D in May 2025 (Katherine Davis/Axios) Oct 23, 2026
Isomorphic Labs Seeks Funding at Valuation of $40 Billion Oct 8, 2026
Sources: Isomorphic Labs, an AI drug discovery startup spun out of Google DeepMind, is in early talks to raise funds at a valuation of at least $40B (Bloomberg) Oct 8, 2026
Alphabet’s Isomorphic Labs in Funding Talks for at Least $40 Billion Value Oct 8, 2026
Colorado-based Enveda, which uses AI to discover new drugs in the natural world, raised a $311M Series E at a $2B valuation, double its valuation a year ago (Marina Temkin/TechCrunch) Sep 23, 2026
Anthropic Life Sciences Head Eric Kauderer-Abrams says the AI startup set up a Bay Area wet lab for physical biology work, as it pushes into disease treatment (Reuters) Sep 18, 2026
Insilico, which uses AI to accelerate drug discovery, says early data shows rentosertib, a drug whose structure was generated with AI's help, could slow aging (Cade Metz/New York Times) Sep 7, 2026
AstraZeneca, Sanofi, Boehringer Back Owkin AI to Cut Drug Bottlenecks Sep 3, 2026
When AI designs a drug, who gets the credit? Aug 21, 2026